Addex Therapeutics (ADXN) Change in Cash (2019 - 2026)

Addex Therapeutics has reported Change in Cash for 8 years, with the latest figure at -$894.4 billion in Q1 2026.

• Quarterly Change in Cash fell 60.6% year-over-year to -$894.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$846.5 billion (down 183.35% YoY) and the FY2025 annual result came in at -$2.1 million, down 189.85% from the prior year.
• Change in Cash slipped to -$894.4 billion in Q1 2026 per ADXN's latest filing, from $604.8 billion in the prior quarter.
• Over five years, Change in Cash peaked at $7737.5 billion in Q2 2023 and troughed at -$10199.7 billion in Q3 2023.
• A 5-year average of -$270.8 billion and a median of -$6.1 million in 2022 frame the typical range for Change in Cash.
• The widest YoY moves for Change in Cash: up 124191321.51% in 2023, down 657267146.71% in 2023.
• Over 5 years, Change in Cash stood at -$14.0 million in 2022, then surged by 75.18% to -$3.5 million in 2023, then soared by 82.87% to -$597015.9 in 2024, then soared by 101305192.64% to $604.8 billion in 2025, then slumped by 247.89% to -$894.4 billion in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$894.4 billion, $604.8 billion, and -$556.9 billion for Q1 2026, Q2 2025, and Q1 2025 respectively.